Low-dose menaquinone-4 improves γ-carboxylation of osteocalcin in young males: a non-placebo-controlled dose–response study

Table 3 Changes in serum ucOC, Gla-OC, and UGR from baseline after MK-4 supplementation

Measurement day	Dosage	ucOC (ng/mL)		Gla-OC (ng/mL)		UGR
Measurement day	Dosage	Median	Range	Median	Range	Median	Range
Day 8	0 μg/day	0.29	(-0.86-3.62)	0.00	(-4.13-6.96)	0.02	(-0.06-0.18)
Day 15	300 μg/day	0.60	(-8.51-2.05)	2.28	(-4.88-13.35)	-0.02	(-1.16-0.10)
Day 22	600 μg/day	-0.72	(-14.30-0.15)*	3.19	(-1.71-19.48)	-0.12	(-1.43-0.01)**
Day 29	900 μg/day	-2.09	(-16.13-0.05)**	1.76	(-1.04-24.54)*	-0.17	(-1.52-0.001)**
Day 36	1500 μg/day	-1.59	(-15.51-0.65)*	4.99	(0.81-31.93)**	-0.16	(-1.53-0.02)**

Data are shown as medians with ranges (minimum, maximum) (n = 13). The changes in serum ucOC levels and the UGR decreased significantly from baseline, whereas the changes in Gla-OC levels increased significantly. *P < 0.05, **P < 0.01 (Friedman’s test and the post hoc Bonferroni-adjusted Wilcoxon signed-rank test).

ISSN: 1475-2891